158 related articles for article (PubMed ID: 35213214)
1. External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.
Oza B; Eisen T; Frangou E; Stewart GD; Bex A; Ritchie AWS; Kaplan R; Smith B; Davis ID; Stockler MR; Albiges L; Escudier B; Larkin J; Joniau S; Hancock B; Hermann GG; Bellmunt J; Parmar MKB; Royston P; Meade A
J Clin Oncol; 2022 Jun; 40(16):1772-1782. PubMed ID: 35213214
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial.
Eisen T; Frangou E; Oza B; Ritchie AWS; Smith B; Kaplan R; Davis ID; Stockler MR; Albiges L; Escudier B; Larkin J; Bex A; Joniau S; Hancock B; Hermann GG; Bellmunt J; Hodgkinson E; Stewart GD; Barber J; Brown J; McMenemin R; Nathan P; Pickering LM; Parmar MKB; Meade A
J Clin Oncol; 2020 Dec; 38(34):4064-4075. PubMed ID: 33052759
[TBL] [Abstract][Full Text] [Related]
3. External validation of the updated Leibovich prognostic models for clear cell and papillary renal cell carcinoma in an Asian population.
Lee HJ; Lee A; Huang HH; Lau WKO
Urol Oncol; 2019 Jun; 37(6):356.e9-356.e18. PubMed ID: 30905510
[TBL] [Abstract][Full Text] [Related]
4. UK Multicenter Prospective Evaluation of the Leibovich Score in Localized Renal Cell Carcinoma: Performance has Altered Over Time.
Vasudev NS; Hutchinson M; Trainor S; Ferguson R; Bhattarai S; Adeyoju A; Cartledge J; Kimuli M; Datta S; Hanbury D; Hrouda D; Oades G; Patel P; Soomro N; Stewart GD; Sullivan M; Webster J; Messenger M; Selby PJ; Banks RE
Urology; 2020 Feb; 136():162-168. PubMed ID: 31705948
[TBL] [Abstract][Full Text] [Related]
5. External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology.
Pichler M; Hutterer GC; Chromecki TF; Jesche J; Kampel-Kettner K; Rehak P; Pummer K; Zigeuner R
J Urol; 2011 Nov; 186(5):1773-7. PubMed ID: 21944989
[TBL] [Abstract][Full Text] [Related]
6. Contemporary external validation of the Leibovich model for prediction of progression after radical surgery for clear cell renal cell carcinoma.
Beisland C; Gudbrandsdottir G; Reisæter LA; Bostad L; Wentzel-Larsen T; Hjelle KM
Scand J Urol; 2015 Jun; 49(3):205-10. PubMed ID: 25423093
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
8. Predicting recurrence and survival in patients with non-metastatic renal-cell carcinoma after nephrectomy: a prospective population-based study with multicenter validation.
Wang Y; Xuan Y; Su B; Gao Y; Fan Y; Huang Q; Zhang P; Gu L; Niu S; Shen D; Li X; Wang B; Zhu Q; Ouyang Z; Xie J; Ma X
Int J Surg; 2024 Feb; 110(2):820-831. PubMed ID: 38016139
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the UCLA Integrated Staging System and the Leibovich score in survival prediction for patients with nonmetastatic clear cell renal cell carcinoma.
Tan MH; Kanesvaran R; Li H; Tan HL; Tan PH; Wong CF; Chia KS; Teh BT; Yuen J; Chong TW
Urology; 2010 Jun; 75(6):1365-1370; 1370.e1-3. PubMed ID: 20022084
[TBL] [Abstract][Full Text] [Related]
10. Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy.
Nguyen DP; Vertosick EA; Corradi RB; Vilaseca A; Benfante NE; Touijer KA; Sjoberg DD; Russo P
Urol Oncol; 2016 Jun; 34(6):259.e1-8. PubMed ID: 26947350
[TBL] [Abstract][Full Text] [Related]
11. A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma.
Morgan TM; Mehra R; Tiemeny P; Wolf JS; Wu S; Sangale Z; Brawer M; Stone S; Wu CL; Feldman AS
Eur Urol; 2018 May; 73(5):763-769. PubMed ID: 29249291
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the pathologic inclusion criteria from contemporary adjuvant clinical trials for predicting disease progression after nephrectomy for renal cell carcinoma.
Kim SP; Crispen PL; Thompson RH; Weight CJ; Boorjian SA; Costello BA; Lohse CM; Leibovich BC
Cancer; 2012 Sep; 118(18):4412-20. PubMed ID: 22952032
[TBL] [Abstract][Full Text] [Related]
13. GRade, Age, Nodes, and Tumor (GRANT) compared with Leibovich score to predict survival in localized renal cell carcinoma: A nationwide study.
Juul S; Donskov F; Clark PE; Lund L; Azawi NH
Int J Urol; 2022 Jul; 29(7):641-645. PubMed ID: 35362146
[TBL] [Abstract][Full Text] [Related]
14. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
15. RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.
Oza B; Frangou E; Smith B; Bryant H; Kaplan R; Choodari-Oskooei B; Powles T; Stewart GD; Albiges L; Bex A; Choueiri TK; Davis ID; Eisen T; Fielding A; Harrison D; McWhirter A; Mulhere S; Nathan P; Rini B; Ritchie A; Scovell S; Shakeshaft C; Stockler MR; Thorogood N; Parmar MKB; Larkin J; Meade A
Contemp Clin Trials; 2021 Sep; 108():106482. PubMed ID: 34538402
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of the Leibovich prognosis score supplemented by vascular invasion for clear cell renal cell carcinoma.
Pichler M; Hutterer GC; Chromecki TF; Jesche J; Groselj-Strele A; Kampel-Kettner K; Pummer K; Zigeuner R
J Urol; 2012 Mar; 187(3):834-9. PubMed ID: 22245331
[TBL] [Abstract][Full Text] [Related]
17. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma.
Beck SD; Patel MI; Snyder ME; Kattan MW; Motzer RJ; Reuter VE; Russo P
Ann Surg Oncol; 2004 Jan; 11(1):71-7. PubMed ID: 14699037
[TBL] [Abstract][Full Text] [Related]
18. Development and External Validation of a Novel Nomogram Predicting Cancer-specific Mortality-free Survival in Surgically Treated Papillary Renal Cell Carcinoma Patients.
Piccinelli ML; Barletta F; Tappero S; Cano Garcia C; Incesu RB; Morra S; Scheipner L; Tian Z; Luzzago S; Mistretta FA; Ferro M; Saad F; Shariat SF; Ahyai S; Longo N; Tilki D; Chun FKH; Terrone C; Briganti A; de Cobelli O; Musi G; Karakiewicz PI
Eur Urol Focus; 2023 Sep; 9(5):799-806. PubMed ID: 37024421
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-11 receptor predicts post-operative clinical outcome in patients with early-stage clear-cell renal cell carcinoma.
Pan D; Xu L; Liu H; Zhang W; Zhu Y; Xu J; Gu J
Jpn J Clin Oncol; 2015 Feb; 45(2):202-9. PubMed ID: 25420690
[TBL] [Abstract][Full Text] [Related]
20. Glutathione peroxidase family and survival prognosis in patients with renal cell carcinoma.
Li J; Huo S; Zhang R; Shi C; Sun N; Liu Q
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 May; 47(5):562-572. PubMed ID: 35753726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
